Coronavirus information

Visitor restrictions, information for patients and more.

View coronavirus information

FOI 0583 Cancer Treatment and Clinical Trials 2019/20

Freedom of Information Request: 0583 2019/20

 

University Hospitals Birmingham NHS Foundation Trust (UHB) completed a merger by acquisition of Heart of England NHS Foundation Trust (HEFT) on 1st April 2018.  Due to historical differences in data collection/reporting across UHB and the former Heart of England NHS Foundation Trust this response has been provided by hospital site.

 

Queen Elizabeth Hospital Birmingham (QEHB)

  1. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)?

11

  1. Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?

Locally advanced: 1

Recurrent metastatic: 0

Unknown: 0

  1. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?

Carboplatin (only or in combination with 5-FU) – 2

Cisplatin (only or in combination with 5-FU) ­- 1

Cetuximab with/without chemotherapy  – 1

Cetuximab with radiotherapy – 0

Pembrolizumab monotherapy – 0

Pembrolizumab with chemotherapy – 0

Nivolumab   – 0

Docetaxel (only or in combination with 5-FU) – 0

Fluorouracil (5FU) – 1

Radiotherapy only – 5

Other – 1

 

Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?

University Hospitals Birmingham – We can confirm that we have 8 studies open at present in the head and neck cancer team

 

Short Title

 

Site

 

Site Status

 

Site Recruitment
Accelerated Platform QEHB Open 159
ART-DECO
QEHB Open 27
CANC 4269
QEHB Closed to recruitment – in follow up 4
CheckMate 651: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 651 QEHB Closed to recruitment – in follow up 5
CompARE Trial QEHB Open 45
Observational study in R/M SCCHN V18Dec2018 QEHB Open 0
PATHOS QEHB Open 4
SEND QEHB Closed to recruitment – in follow up 20

 

 

  1. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];

0 FOR ALL

 

Aflibercept

Bevacizumab

Capecitabine

CAPIRI

CAPOX

Cetuximab not in combination with FOLFIRI or FOLFOX

Cetuximab in combination with FOLFIRI

Cetuximab in combination with FOLFOX

Irinotecan

FOLFIRI

FOLFOX

Oxaliplatin

Panitumumab not in combination with FOLFIRI or FOLFOX

Panitumumab in combination with FOLFIRI

Panitumumab in combination with FOLFOX

Nivolumab

Raltitrexed

Ramucirumab

Regorafenib

Sorafenib

5FU only

Tegafur Uracil + 5FU

Trifluridine–tipiracil

XELOX

Other

 

  1. Within your health trust how many patients have been treated in the past 6 months with the following agent for Renal Cell Carcinoma:

Sunitinib – 2

Avelumab + Axitinib – 0

Axinitib – 0

Cabozantinib – 0

Everolimus – 0

Lenvantinib + Everolimus – 0

Nivolumab  – 1

Nivolumab + Ipilimumab – 0

Pazopanib – 1

Pembrolizumab + Axitinib – 0

Sunitinib – 0

Temsirolimus – 0

Tivozanib – 0

 

  1. Does your health trust participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?

University Hospitals Birmingham – We can confirm that we have 2 studies open at present for patients with Renal Cell Cancer

Short Title

 

Site

 

Site Status

 

Site Recruitment
SORCE QEHB Open 0
STAR Standard vs Modified Drug Therapy in Renal Cancer Heartlands Hospital Closed to recruitment – in follow up 3

 

Heartlands, Good Hope and Solihull Hospitals (HGS)

  1. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)?

Not Applicable

 

  1. Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?

Not Applicable

 

  1. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?

Not Applicable

 

Carboplatin (only or in combination with 5-FU)

Cisplatin (only or in combination with 5-FU) ­

Cetuximab with/without chemotherapy  

Cetuximab with radiotherapy

Pembrolizumab monotherapy

Pembrolizumab with chemotherapy

Nivolumab  

Docetaxel (only or in combination with 5-FU)

Fluorouracil (5FU)

Radiotherapy only

Other

 

Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?

 

University Hospitals Birmingham – We can confirm that we have 8 studies open at present in the head and neck cancer team

 

Short Title

 

Site

 

Site Status

 

Site Recruitment
Accelerated Platform QEHB Open 159
ART-DECO
QEHB Open 27
CANC 4269
QEHB Closed to recruitment – in follow up 4
CheckMate 651: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 651 QEHB Closed to recruitment – in follow up 5
CompARE Trial QEHB Open 45
Observational study in R/M SCCHN V18Dec2018 QEHB Open 0
PATHOS QEHB Open 4
SEND QEHB Closed to recruitment – in follow up 20

 

  1. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];

Aflibercept – 0

Bevacizumab – 0

Capecitabine – 28

CAPIRI

CAPOX

Cetuximab not in combination with FOLFIRI or FOLFOX

Cetuximab in combination with FOLFIRI

Cetuximab in combination with FOLFOX

Irinotecan – 2

FOLFIRI

FOLFOX

Oxaliplatin

Panitumumab not in combination with FOLFIRI or FOLFOX

Panitumumab in combination with FOLFIRI

Panitumumab in combination with FOLFOX

Nivolumab – 1

Raltitrexed

Ramucirumab

Regorafenib

Sorafenib

5FU only – 8

Tegafur Uracil + 5FU

Trifluridine–tipiracil

XELOX

Other

 

  1. Within your health trust how many patients have been treated in the past 6 months with the following agent for Renal Cell Carcinoma:

Sunitinib

Avelumab + Axitinib – 4

Axinitib

Cabozantinib – 8

Everolimus

Lenvantinib + Everolimus

Nivolumab  – 7

Nivolumab + Ipilimumab – 6

Pazopanib – 15

Pembrolizumab + Axitinib

Sunitinib – 7

Temsirolimus

Tivozanib

 

  1. Does your health trust participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?

 

University Hospitals Birmingham – We can confirm that we have 2 studies open at present for patients with Renal Cell Cancer

Short Title

 

Site

 

Site Status

 

Site Recruitment
SORCE QEHB Open 0
STAR Standard vs Modified Drug Therapy in Renal Cancer Heartlands Hospital Closed to recruitment – in follow up 3

Thinking of going to Accident and Emergency but not sure if you need to? Try our handy symptom checker.

Try ask A&E

We're improving the accessibility of our websites. If you can't access any content or if you would like to request information in another format, please view our accessibility statement.